A Z S Rohatiner

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi The clinical course of follicular lymphoma
    Ama Z S Rohatiner
    Cancer Research UK, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, UK
    Best Pract Res Clin Haematol 18:1-10. 2005
  2. ncbi Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up
    Ama Z S Rohatiner
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 25:2554-9. 2007
  3. ncbi Meta-analysis to evaluate the role of interferon in follicular lymphoma
    A Z S Rohatiner
    Department of Medical Oncology, St Bartholomew s Hospital, 45 Little Britain, London, EC1A 7BE, United Kingdom
    J Clin Oncol 23:2215-23. 2005
  4. ncbi Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care
    A C Gordon
    Department of Anaesthesia and Intensive Care, Barts and The London Queen Mary s School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London, EC1A 7BE, UK
    Anaesthesia 60:340-7. 2005
  5. ncbi Waldenstrom's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001
    S Ngan
    Department of Medical Oncology, St Bartholomew s Hospital and Cancer Research, London, UK
    Semin Oncol 30:236-8. 2003
  6. ncbi Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting
    D C Taussig
    Department of Medical Oncology, 45 Little Britain, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Oncol 21:3060-5. 2003
  7. ncbi Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study
    S Montoto
    Cancer Research UK Medical Oncology Unit, Institute of Cancer, Centre for Medical Oncology, Barts and The London, Queen Mary s School of Medicine and Dentistry, London, UK
    Leukemia 21:2324-31. 2007
  8. ncbi Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia
    D M Lillington
    Cancer Research UK, Department of Medical Oncology, St Bartholomew s Hospital, London
    Ann Oncol 13:40-3. 2002
  9. ncbi Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    A J Davies
    Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, 45 Little Britain, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Oncol 22:1469-79. 2004
  10. ncbi ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease
    J A Radford
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    J Clin Oncol 20:2988-94. 2002

Collaborators

Detail Information

Publications18

  1. ncbi The clinical course of follicular lymphoma
    Ama Z S Rohatiner
    Cancer Research UK, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, UK
    Best Pract Res Clin Haematol 18:1-10. 2005
    ..It is hoped that the advent of new treatment modalities will alter the inexorable pattern of recurrence...
  2. ncbi Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up
    Ama Z S Rohatiner
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 25:2554-9. 2007
    ....
  3. ncbi Meta-analysis to evaluate the role of interferon in follicular lymphoma
    A Z S Rohatiner
    Department of Medical Oncology, St Bartholomew s Hospital, 45 Little Britain, London, EC1A 7BE, United Kingdom
    J Clin Oncol 23:2215-23. 2005
    ..To determine whether interferon (IFN) -alpha2, when given with or following chemotherapy, influences response rate, remission duration, and survival in newly diagnosed patients with follicular lymphoma...
  4. ncbi Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care
    A C Gordon
    Department of Anaesthesia and Intensive Care, Barts and The London Queen Mary s School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London, EC1A 7BE, UK
    Anaesthesia 60:340-7. 2005
    ..There was close agreement between actual and predicted mortality with increasing Simplified Acute Physiology Score II for all patients, including those not admitted to intensive care...
  5. ncbi Waldenstrom's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001
    S Ngan
    Department of Medical Oncology, St Bartholomew s Hospital and Cancer Research, London, UK
    Semin Oncol 30:236-8. 2003
    ..This retrospective analysis confirms that chlorambucil is an effective first-line agent in WM and has activity when used at subsequent relapse...
  6. ncbi Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting
    D C Taussig
    Department of Medical Oncology, 45 Little Britain, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Oncol 21:3060-5. 2003
    ..To evaluate the use of reduced-intensity (RI) conditioning with allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical family donors in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...
  7. ncbi Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study
    S Montoto
    Cancer Research UK Medical Oncology Unit, Institute of Cancer, Centre for Medical Oncology, Barts and The London, Queen Mary s School of Medicine and Dentistry, London, UK
    Leukemia 21:2324-31. 2007
    ..This long follow-up study shows a plateau in the PFS curve, suggesting that a selected group of patients might be cured with HDT. On the downside, TBI-containing regimens are associated with a negative impact on survival...
  8. ncbi Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia
    D M Lillington
    Cancer Research UK, Department of Medical Oncology, St Bartholomew s Hospital, London
    Ann Oncol 13:40-3. 2002
    ..This retrospective study was used to detect evidence of abnormal therapy-related myelodysplasia/secondary acute myeloid leukaemia (tMDS/sAML) clones before HDT in a subset of patients who subsequently developed secondary neoplasia...
  9. ncbi Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    A J Davies
    Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, 45 Little Britain, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Oncol 22:1469-79. 2004
    ..An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma...
  10. ncbi ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease
    J A Radford
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    J Clin Oncol 20:2988-94. 2002
    ....
  11. ncbi Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma
    Kim W Last
    Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, St Bartholomew s Hospital, London EC1M 6BQ, United Kingdom
    J Clin Oncol 21:2335-41. 2003
    ..This study was undertaken to test the hypothesis that serum selenium concentration at presentation correlates with dose delivery, first treatment response, and overall survival in patients with aggressive B-cell non-Hodgkin's lymphoma...
  12. ncbi High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma
    Ama Z S Rohatiner
    Department of Medical Oncology, St Bartholomew s Hospital, 45 Little Britain, London EC1A 7BE, UK
    Best Pract Res Clin Haematol 15:467-80. 2002
    ..In follicular lymphoma, there is a correlation between freedom from recurrence and persistent PCR negativity for bcl-2 rearrangement-containing cells in follow-up bone marrow samples...
  13. ncbi Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma
    Silvia Montoto
    Cancer Research UK Medical Oncology Unit, Barts and The London, Queen Mary s School of Medicine and Dentistry, United Kingdom
    J Clin Oncol 25:2426-33. 2007
    ..To study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL) in patients with follicular lymphoma (FL)...
  14. ncbi Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine
    Christopher D Dalley
    I C R F Medical Oncology Unit, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, UK
    Hematol J 3:237-43. 2002
    ..These results confirm that although elderly patients have a poor outcome, prognostic factors can be identified that influence treatment outcome in this important group of patients...
  15. pmc Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management
    Marco Gerlinger
    CR UK Medical Oncology Unit, St Bartholomew s Hospital, Barts and the London School of Medicine and Dentistry, 45 Little Britain, EC1A 7BE London, United Kingdom
    Haematologica 95:1130-5. 2010
    ....
  16. ncbi The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction
    Karin E Summers
    Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, Charterhouse Square, London EC1M 6BQ, UK
    Br J Haematol 118:563-6. 2002
    ..These findings suggest that, in remission, PB may be adequately monitored. In general, however, higher copy number was detected in BM than in the corresponding PB sample...
  17. ncbi Primary follicular lymphoma of the testis and epididymis in adults
    Chris M Bacon
    Department of Pathology, University of Cambridge, Box 231, Level 3 Lab Block, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Am J Surg Pathol 31:1050-8. 2007
    ....
  18. ncbi Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study
    Anthony J Swerdlow
    Section of Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Natl Cancer Inst 99:206-14. 2007
    ....